MORF - Morphic reports positive interim results in early-stage trial for inflammatory bowel disease

Today, Morphic Therapeutic ([[MORF]] +140.8%) announced positive interim results from its Phase 1 clinical trial of MORF-057 for the treatment of inflammatory bowel disease.The key pharmacodynamic measurement in the trial was receptor occupancy (RO), the percentage of ?4?7 bound by MORF-057, 12 hours after the single doses ranging from 25 mg to 400 mg.Across the three highest dose cohorts, ORF-057 achieved more than 95% mean ?4?7 RO with >99% RO in subjects in each cohort above 25mg.The oral small-molecule inhibitor of the ?4?7 integrin was well tolerated in all 5 cohorts in Phase 1 SAD trial with no serious adverse events (SAEs) and no significant lab abnormalities in any subject.In the Phase 1 program, the enrollment is ongoing for two additional groups following which the company expects to release the full data set at a medical meeting in mid-2021.“We’re excited to present the totality of the Phase 1 trial data later this

For further details see:

Morphic reports positive interim results in early-stage trial for inflammatory bowel disease